Navigation Links
China PharmaHub Signs Distribution Agreement with Integrated Biometrics
Date:11/10/2010

BOSTON, Nov. 10, 2010 /PRNewswire/ -- China PharmaHub Corp. (OTC Bulletin Board: CPHB) ("PharmaHub") announced it has signed an agreement to be a distributor for Integrated Biometrics ("IB"), a provider of high performance fingerprint biometric identity solutions.  PharmaHub will have the exclusive distribution rights in China, Hong Kong, Taiwan and Macau (the "Greater China Region") to sell IB products to customers in the Pharmaceutical, Biotechnology, Healthcare, Lock Manufacturing and Safe Manufacturing industries. Additionally, PharmaHub will have the non-exclusive right to sell such products to other industries in the Greater China Region.

IB develops and manufactures fingerprint-based biometric identification systems which result in highly dependable logical and physical access control solutions.  IB's patented Light Emitting Sensor technology is the cutting edge in biometric fingerprint identification and provides a superior combination of security, usability and durability. With China's biometrics market growing at a rate of 50% per annum, its market is expected to reach 3 billion RMB by the end of 2010, PharmaHub and IB believe they are well-positioned to capitalize on this growing market.

Richard Lui, President of PharmaHub, said "We are very excited to be working with industry leaders such as IB.  PharmaHub's growing distribution channel of 2,600 hospitals and ties to China's healthcare industry present very exciting opportunities for sales of IB products.  Working with successful companies such as Integrated Biometrics embodies the PharmaHub model."

Lui concluded, "We started PharmaHub with the goal of eventually becoming a global pharmaceutical 'HUB'.  Since the founding of PharmaHub in July 2009, we have worked non-stop to build a foundation of strategic alliances, partnerships and joint ventures."  

The following are the highlights of PharmaHub's development since September 2009:

  • September 15, 2009 – We entered into an Exclusive Business Cooperation Agreement with the PRC National Engineering Research Center, a reputable quasi-government owned Research Institute in China which will assist us in conducting preclinical and clinical studies with the State Food and Drug Administration of the People's Republic of China.
  • June 15, 2010 – We entered into a Definitive Agreement with David Weaver and Michael Rynkiewicz to develop a Humanized Antibody Platform created by Drs. Weaver and Rynkiewicz.
  • June 15, 2010 - We incorporated our first Joint Venture, Akanas Therapeutics, Inc. with Drs. Weaver and Rynkiewicz to further our objectives with respect to the Humanized Antibody Platform.
  • July 1, 2010 – We gained access to a 2,600 hospital distribution network in China pursuant to our Cooperation Agreement with Chengdu Yongkon Pharmacy Co., Ltd.
  • July 1, 2010 – We formed an alliance with the Sichuan Provincial Government to promote technological exchange and transfer between China and the United States, with a focus upon the bio-pharmaceutical and medical device industries.
  • August 17, 2010 – We entered into an Exclusive Distributor Agreement with a world leader in precision glass technology to sell a "Magic Bullet" Liver Cancer Therapy in China, Hong Kong, Taiwan, Macau, Singapore, Malaysia and Bangladesh.

  • About PharmaHub:China PharmaHub Corp. is a development stage company engaged in entering into the business of acquiring, developing and commercializing innovative products of biopharmaceutical companies based in the United States or China which treat a variety of human diseases.  PharmaHub intends to focus upon investing into or licensing the rights, with respect to countries where such companies currently have minimal presence, to develop, commercialize, market and sell pharmaceutical, biotechnology and related technologies which address important unmet medical needs, offer improved, cost-effective alternatives to current methods of treatment or enable the discovery, research and development of new medicines.  Management believes that PharmaHub brings a unique blend of relationships and resources to assist scientists and companies in bringing their ideas to reality.  PharmaHub's corporate headquarters are located in Los Angeles and Boston. For more information visit www.chnpharmahub.com.

    Forward-Looking StatementsThis press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein. Contact:Monica DingChief Financial OfficerTel: (909)843-6388Email: ir@chnpharmahub.com
    '/>"/>

    SOURCE China PharmaHub Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology news :

    1. Study examines risk of heterosexual HIV transmission in China
    2. Virginia Techs Mueller receives friendship award from China
    3. University of Utah microbubbles clean dirty soil in China
    4. Measurements of CO2 and CO in Chinas air indicate sharply improved combustion efficiency
    5. Chinas environmental challenges have global implications
    6. Potential industrial and agricultural uses of echinacea trump health claims
    7. Elsevier and Peking University Health Science Center develop new China online CME service
    8. Porous China-Myanmar border allowing illegal wildlife trade
    9. Exploring Echinaceas enigmatic origins
    10. HFSP President Arima and Secretary General Winnacker awarded for fostering cooperation with China
    11. Poisonous prehistoric raptor discovered by research team from Kansas and China
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
    (Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
    (Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
    Breaking Biology News(10 mins):
    (Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
    (Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
    (Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
    (Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
    Breaking Biology Technology: